Article
Metabolic Signatures of Dual mTOR Inhibition in Diffuse Large B-Cell Lymphoma
2026-03-11
Abstract excerpt
<title>Abstract</title> <p> Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous malignancy in which many patients relapse or fail to respond to standard therapies. Constitutive activation of the mechanistic target of rapamycin (mTOR) pathway, involving both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), promotes tumor growth and metabolic reprogramming. First-generation inhibitors targ...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- c5538f00-37c1-54b9-9d96-5c5a9cd49345
- DOI
- 10.21203/rs.3.rs-8928389/v1
